Предсърдно мъждене и сърдечна недостатъчност – патофизиологична взаимовръзка, клинични прояви и прогностично значение
Ключови думи :
предсърдно мъждене, сърдечна недостатъчност, патофизиологични механизми, предсърдно ремоделиране, прогнозаАбстракт
Настоящият обзор обобщава съвременните данни за патофизиологичните механизми, клиничните прояви и прогностичното значение на взаимовръзката между ПМ и СН и подчертава необходимостта от интегриран диагностичен и терапевтичен подход. Тези заболявания често съществуват едновременно и са свързани чрез изразена двупосочна патофизиологична и клинична взаимозависимост. ПМ може да допринесе за развитието и прогресията на СН чрез загуба на предсърдния принос към камерното пълнене, нерегулярен и ускорен камерен ритъм и развитие на тахикардно-индуцирана кардиомиопатия. От друга страна, структурното и функционално ремоделиране на миокарда, хемодинамичните промени и неврохормоналната активация при СН създават благоприятен субстрат за възникване и поддържане на ПМ. Съчетанието на двете състояния е асоциирано с по-тежка симптоматика, по-чести хоспитализации и неблагоприятна дългосрочна прогноза, независимо от фенотипа на СН.
Литература (библиография)
Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414.
Joglar JA, Chung MK, Armbruster AL et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2024 Jan 2 [cited 2026 Jan 6];149(1). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193.
Karatela MF, Calkins H. The Global Impact of Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2025;14:e28.
Heeringa J, Van Der Kuip DAM, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr 1;27(8):949-953.
Sagris M, Vardas EP, Theofilis P et al. Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. IJMS. 2021;23(1):6.
Elliott AD, Middeldorp ME, Van Gelder IC et al. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20(6):404-417.
McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
McDonagh TA, Metra M, Adamo M et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639.
Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2022 May 3 [cited 2026 Jan 5];145(18). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
Bozkurt B, Ahmad T, Alexander K et al. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America. Journal of Cardiac Failure. 2025;31(1):66-116.
Jia Z, Du X. Epidemiology and Burden of Heart Failure. Cardiology Discovery. 2025;5(4):281-284.
Khan MS, Shahid I, Bennis A et al. Global epidemiology of heart failure. Nat Rev Cardiol. 2024t;21(10):717-734.
Lund LH, Crespo-Leiro MG, Laroche C et al. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry. Eur J Heart Fail. 2024;26(12):2487-2501.
Bidaoui G, Assaf A, Marrouche N. Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities. Curr Heart Fail Rep. 2025;22(1):3.
Corica B, Romiti GF, Proietti M et al. Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Re-
gistry Phase III. Eur J reventive Cardiol. 2025;zwaf485.
Kim YG. Interaction Between Heart Failure and Atrial Fibrillation. Int J Heart Fail. 2022;4(3):139.
Gorter TM, Van Veldhuisen DJ, Mulder BA et al. Prevalence and Incidence of Atrial Fibrillation in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: (Additive) Value of Implantable Loop Recorders. JCM. 2023;12(11):3682.
Kroshian G, Joseph J, Kinlay S et al. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis. Cardiovasc electrophysiol. 2024;35(4):715–26.
Ariyaratnam JP, Elliott AD, Mishima RS et al. Heart failure with preserved ejection fraction: An alternative paradigm to explain the clinical implications of atrial fibrillation. Heart Rhythm O2. 2021;2(6):771–83.
Cheng Y, Deng H, Wei H et al. Association Between Age at Diagnosis of Atrial Fibrillation and Subsequent Risk of Ischemic Stroke. JAHA. 2025;14(4):e038367.
Al-Shoaibi NA, Ashram WY, Mokhtar AT et al. Non-genetic Risk Factors for Atrial Fibrillation in Individuals Aged 60 and Above. J Pioneering Med Sci. 2025;14(09):1-5.
Gomez SE, Fazal M, Nunes JC et al. Racial, ethnic, and sex disparities in atrial fibrillation management: rate and rhythm control. J Interv Card Electrophysiol. 2022;66(5):1279-1290.
Leventopoulos G, Koros R, Travlos C et al. Mechanisms of Atrial Fibrillation: How Our Knowledge Affects Clinical Practice. Life. 2023;13(6):1260.
Mosca L, Barrett-Connor E, Kass Wenger N. Sex/Gender Differences in Cardiovascular Disease Prevention: What a Difference a Decade Makes. Circulation. 2011 Nov 8;124(19):2145-2154.
Westerman S, Wenger N. Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes. Curr Cardiol Rev. 2019;15(2):136-144.
Lubitz SA, Yi BA, Ellinor PT. Genetics of Atrial Fibrillation. Heart Failure Clinics. 2010 Apr;6(2):239-247.
Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circulation Research. 2020 Jun 19;127(1):21–33.
Middeldorp ME, Ariyaratnam JP, Kamsani SH et al. Hypertension and atrial fibrillation. Journal of Hypertension. 2022 Dec;40(12):2337-52.
Aune D, Mahamat-Saleh Y, Kobeissi E et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023 Feb;38(2):145-78.
Gadde S, Kalluru R, Cherukuri SP et al. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus [Internet]. 2022 Aug 7 [cited 2026 Jan 8]; Available from: https://www.cureus.com/articles/107776-atrial-fibrillation-in-chronic-kidney-disease-an-overview
Tavares L, Lador A, Valderrábano M. Sleep Apnea and Atrial Fibrillation: Role of the Cardiac Autonomic Nervous System. Methodist DeBakey Cardiovascular Journal. 2021 Jan 1;17(1):48.
Grigoriou K, Karakasis P, Pamporis K, Theofilis P, Patoulias D, Karagiannidis E, et al. Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies. CIMB. 2025 Jul 17;47(7):559.
Lancellotti P, Miraglia V. Valvular heart disease and atrial fibrillation: advances in mechanisms, risk stratification, and therapeutic approaches. Acta Cardiologica. 2025 Jul 3;80(6):535–40.
Karakasis P, Theofilis P, Vlachakis PK et al. Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets. IJMS. 2024 Dec 30;26(1):209.
Daly DJ, Essien UR, Del Carmen MG et al. Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature. Journal of the National Medical Association. 2023 Jun;115(3):290-297.
Siddiqi HK, Vinayagamoorthy M, Gencer B et al. Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study. JAMA Cardiol. 2022;7(10):1027.
González A, Ravassa S, López B et al. Myocardial Remodeling in Hypertension: Toward a New View of Hypertensive Heart Disease. Hypertension. 2018 Sep;72(3):549-558.
Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-626.
Kim S, Jeong Y, Kim YL et al. Association of Chronic Kidney Disease With Atrial Fibrillation in the General Adult Population: A Nationwide Population-Based Study. JAHA. 2023 Apr 18;12(8):e028496.
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. International Journal of Stroke. 2021;16(2):217-221.
Chousou PA, Chattopadhyay R, Tsampasian V et al. Electrocardiographic Predictors of Atrial Fibrillation. Medical Sciences. 2023;11(2):30.
Bayés De Luna A, Fiol-Sala M et al. Clinical Electrocardiography: A Textbook [Internet]. 1st ed. Wiley; 2021 [cited 2026 Jan 26]. Available from: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536475
Huang Z, Zheng Z, Wu B et al. Predictive value of P wave terminal force in lead V1 for atrial fibrillation: A meta-analysis. Noninvasive Electrocardiol. 2020;25(4):e12739.
Frąk W, Wojtasińska A, Lisińska W et al. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. Biomedicines. 2022;10(8):1938.
Atabekov T, Batalov R, Archakov E et al. Predictors of Atrial Fibrillation in Heart Failure Patients with Indications for ICD Implantation. JCM. 2025;14(12):4358.
Grassi G, Biffi A, Seravalle G et al. Sympathetic Neural Overdrive in the Obese and Overweight State: Meta-analysis of published studies. Hypertension. 2019;74(2):349–58.
Nso N, Bookani KR, Metzl M, Radparvar F. Role of inflammation in atrial fibrillation: A comprehensive review of current knowledge. Journal of Arrhythmia. 2021;37(1):1-10.
Gorczyca-Głowacka I, Galas A, Tymińska A et al. Atrial fibrillation in patients with heart failure with reduced, mildly reduced, and preserved ejection fraction: A report from the HEart failuRe ObsErvational Study (HEROES). Pol Heart J. 2025;83(6):701-708.
Chen P, Yin X, Ren L. Construction and validation of a predictive model for the risk of atrial fibrillation in patients with heart failure with preserved ejection fraction: a single-center retrospective analysis. BMC Cardiovasc Disord. 2025 Dec 23;25(1):873.
Schupp T, Schmitt A, Reinhardt M et al. Prognosis and treatment strategies for atrial fibrillation in heart failure with mildly reduced ejection fraction. Eur J Preventive Cardiol. 2024;31(11):1372-1384.
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Публикация с Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Можете свободно да споделяте, копирате и разпространявате материала във всякакъв носител или формат при следните условия.
Списание Bulgarian Medical Journal (Български медицински журнал / Bulgarian Medical Journal) ISSN: 1313-1516 (Print)
